Therapeutic strategies for postremission treatment in childhood acute myeloid leukemia (AML). The AIEOP experience 1987-1991.

abstract：:This work represents an update of our experience on mobilization and transplantation of peripheral blood progenitor cells (PBPC) collected during the early recovery phase after chemotherapy in patients with chronic myelogenous leukemia. The collection of Ph-negative precursor cells occurred in 13/19 (68%) patients mob...

journal_title：Leukemia

authors： Frassoni F,Carella AM

更新日期：1996-06-01 00:00:00

abstract：:CAMAL (common antigen in myelogenous acute leukemia) is an antigenic preparation isolated in this laboratory from the bone marrow or peripheral blood cells of persons with myeloid leukemias and shown in an immunoperoxidase slide test to be diagnostic of these leukemias. CAMAL has been shown to be inhibitory to myelopo...

journal_title：Leukemia

authors： Leitch HA,Buskard N,Levy JG

更新日期：1993-09-01 00:00:00

abstract：:Most modern treatment protocols for acute lymphoblastic leukaemia (ALL) include the analysis of minimal residual disease (MRD). To ensure comparable MRD results between different MRD-polymerase chain reaction (PCR) laboratories, standardization and quality control are essential. The European Study Group on MRD detecti...

journal_title：Leukemia

authors： van der Velden VH,Cazzaniga G,Schrauder A,Hancock J,Bader P,Panzer-Grumayer ER,Flohr T,Sutton R,Cave H,Madsen HO,Cayuela JM,Trka J,Eckert C,Foroni L,Zur Stadt U,Beldjord K,Raff T,van der Schoot CE,van Dongen JJ,Euro

更新日期：2007-04-01 00:00:00

abstract：:In most cases of lymphomas with blood dissemination, the careful cytological analysis of peripheral blood smears provides a rapid orientation to diagnosis, even if the final subtyping is achieved by histology and eventually other techniques. Here, we evaluated if the analysis of blood smears may suggest the blood diss...

journal_title：Leukemia

authors： Baseggio L,Berger F,Morel D,Delfau-Larue MH,Goedert G,Salles G,Magaud JP,Felman P

更新日期：2006-02-01 00:00:00

abstract：:Bortezomib is a potent drug for the treatment of multiple myeloma. Its anti-tumor activity is mediated by proteasome inhibition leading to decreased cell proliferation and induction of apoptosis. However, an unimpaired proteasomal function plays a crucial role for the induction of anti-tumor immunity by dendritic cell...

journal_title：Leukemia

authors： Straube C,Wehner R,Wendisch M,Bornhäuser M,Bachmann M,Rieber EP,Schmitz M

更新日期：2007-07-01 00:00:00

abstract：:The acquired kinase mutation JAK2V617F plays a central role in myeloproliferative neoplasms (MPNs). However, the mechanisms responsible for the malignant hematopoietic stem/progenitor cell (HSPC) expansion seen in patients with MPNs are not fully understood, limiting the effectiveness of current treatment. Endothelial...

journal_title：Leukemia

authors： Zhan H,Lin CHS,Segal Y,Kaushansky K

更新日期：2018-02-01 00:00:00

abstract：:Mast cell leukemia (MCL) is a highly fatal malignancy characterized by devastating expansion of immature mast cells in various organs. Although considered a stem cell disease, little is known about MCL-propagating neoplastic stem cells. We here describe that leukemic stem cells (LSCs) in MCL reside within a CD34+/CD38...

journal_title：Leukemia

authors： Eisenwort G,Sadovnik I,Schwaab J,Jawhar M,Keller A,Stefanzl G,Berger D,Blatt K,Hoermann G,Bilban M,Willmann M,Winding C,Sperr WR,Arock M,Rülicke T,Reiter A,Valent P

更新日期：2019-11-01 00:00:00

abstract：:Mesenchymal stromal cells (MSCs) are multipotent cells, which exhibit broad immunosuppressive activities. Moreover, they may be administered irrespectively of human leukocyte antigen (HLA) compatibility, without inducing life-threatening immunological reactions, as they express no HLA class II and limited HLA class I ...

journal_title：Leukemia

authors： Balan A,Lucchini G,Schmidt S,Schneider A,Tramsen L,Kuçi S,Meisel R,Bader P,Lehrnbecher T

更新日期：2014-10-01 00:00:00

abstract：:Chromosomal breakpoints associated with malignancy are known to cluster at particular regions of the karyotype. Based on a review of the literature we have identified a novel leukaemia syndrome associated with translocations involving 8p11. This syndrome is distinct from the previously described translocation t(8;16)(...

journal_title：Leukemia

authors： Macdonald D,Aguiar RC,Mason PJ,Goldman JM,Cross NC

更新日期：1995-10-01 00:00:00

abstract：:Ligation of CD40 on chronic lymphocytic leukemia (CLL) cells induces phenotypic and biochemical changes that facilitate CLL cell-T cell interactions and enhances the sensitivity of CLL cells to clearance by adaptive and innate immune-effector mechanisms. CLL cells can be transduced to express CD40 ligand (CD154) using...

journal_title：Leukemia

authors： Wierda WG,Castro JE,Aguillon R,Sampath D,Jalayer A,McMannis J,Prussak CE,Keating M,Kipps TJ

更新日期：2010-11-01 00:00:00

abstract：:Thirty-two adult patients with acute leukemia were treated with continuous infusion carboplatin and etoposide at eight different dose levels. Dose limiting toxicity was encountered at doses of carboplatin of 310 mg/m2 per day for 5 days (total 1550 mg/m2 per course) and etoposide 150 mg/m2 per day for 5 days (total do...

journal_title：Leukemia

authors： Lee EJ,Reck K,Carter C,Hodges S,Schiffer CA

更新日期：1993-10-01 00:00:00

abstract：:Dasatinib treatment markedly increases the number of large granular lymphocytes (LGLs) in a proportion of Ph+ leukemia patients, which associates with a better prognosis. The lymphocytosis is predominantly observed in cytomegalovirus (CMV)-seropositive patients, yet detectable CMV reactivation exists only in a small f...

journal_title：Leukemia

authors： Ishiyama K,Kitawaki T,Sugimoto N,Sozu T,Anzai N,Okada M,Nohgawa M,Hatanaka K,Arima N,Ishikawa T,Tabata S,Onaka T,Oka S,Nakabo Y,Amakawa R,Matsui M,Moriguchi T,Takaori-Kondo A,Kadowaki N

更新日期：2017-01-01 00:00:00

abstract：:Expression of the human multidrug resistance 1 gene (MDR1), which encodes the P-glycoprotein transmembrane efflux pump, has been associated with treatment failure of some leukemias, primarily acute myeloid leukemia (AML). To elucidate the epigenetic events associated with overexpression of MDR1 in AML, we analyzed the...

journal_title：Leukemia

authors： Fryxell KB,McGee SB,Simoneaux DK,Willman CL,Cornwell MM

更新日期：1999-06-01 00:00:00

abstract：:The t(1;19)(q23;p13), a non-random chromosome rearrangement associated with childhood pre-B acute lymphoblastic leukemia (ALL), results at molecular level in the hybrid E2A-PBX1 gene. This gene is expressed in a typical set of fusion transcripts and oncogenic chimeric proteins. However, the occurrence of t(1;19) molec...

journal_title：Leukemia

authors： Privitera E,Luciano A,Ronchetti D,Aricò M,Santostasi T,Basso G,Biondi A

更新日期：1994-04-01 00:00:00

abstract：:Polymerase chain reaction (PCR) techniques based on amplification and identification of leukemia-specific DNA sequences provide a sensitive diagnostic method for detection of minimal residual disease (MRD) with a detection limit of 10(-5) to 10(-6) (1-10 malignant cells in 10(6) normal cells). To date, the main leukem...

journal_title：Leukemia

authors： Breit TM,Beishuizen A,Ludwig WD,Mol EJ,Adriaansen HJ,van Wering ER,van Dongen JJ

更新日期：1993-12-01 00:00:00

abstract：:All-trans retinoic acid (ATRA) has recently been shown to synergize with the inhibitory effect of interferon alpha (IFN alpha) on the growth of malignant cells isolated from solid tumors. We investigated whether ATRA could potentiate the inhibitory effects of IFN alpha on the proliferation of leukemic progenitors in c...

journal_title：Leukemia

authors： Mahon FX,Chahine H,Barbot C,Pigeonnier V,Jazwiec B,Reiffers J,Ripoche J

更新日期：1997-05-01 00:00:00

abstract：:The aim was to determine the efficacy and safety of decitabine in the settings of relapse post-allogeneic progenitor cell transplantation or as part of the conditioning regimen. Three patients (two AML, one ALL) received single agent decitabine 1000 mg/m2 total dose) for treatment of relapse post-transplant (group 1)....

journal_title：Leukemia

authors： Giralt S,Davis M,O'Brien S,van Besien K,Champlin R,de Vos D,Kantarjian H

更新日期：1997-03-01 00:00:00

abstract：:A lot of genes deregulated in malignant plasma cells (PCs) involved in multiple myeloma have been reported these last years. The expression of some of these genes is associated with poor survival. A critical step is to elucidate the biological mechanisms triggered by these gene products. Such studies are hampered by t...

journal_title：Leukemia

authors： Schoenhals M,Frecha C,Bruyer A,Caraux A,Veyrune JL,Jourdan M,Moreaux J,Cosset FL,Verhoeyen E,Klein B

更新日期：2012-07-01 00:00:00

abstract：:In a study carried out for patients receiving intrafamilial HLA-A,B,DR identical, MLC negative bone marrow transplants, RFLP profiles of HLA-class II for 27 donor recipient pairs were analyzed. Twenty-four pairs were found HLA-class II identical while three pairs were HLA-DP incompatible. The patients of these three p...

journal_title：Leukemia

authors： al-Daccak R,Loiseau P,Soulie A,Varrin F,Rabian C,Raffoux C,Cohen D,Degos L,Gluckman E,Colombani J

更新日期：1990-03-01 00:00:00

abstract：:With the sequencing of the human genome and the development of new genomic technologies, biomedical discovery has been transformed. The applications of these new approaches are ever-expanding from disease classification, to identification of new targets, to outcome prediction. A logical next step is the integration of...

journal_title：Leukemia

authors： Stegmaier K

更新日期：2009-07-01 00:00:00

abstract：:CD13/aminopeptidase N (APN) is a cell surface metallopeptidase expressed by normal and leukemic myeloid cells, and by lymphoblasts in 5-10% of acute lymphoid leukemia (ALL) cases, previously classified as 'biphenotypic' or 'mixed-lineage' leukemias. In fresh cells from two early B-lineage, t(9;22)-positive, ALL cases ...

journal_title：Leukemia

authors： Saito M,Kumagai M,Okazaki T,Nakazawa S,Shapiro LH,Look AT,Campana D

更新日期：1995-09-01 00:00:00

abstract：:MUM1 (multiple myeloma oncogene 1)/IRF4 (interferon regulatory factor 4) is a transcription factor that is activated as a result of t(6;14)(p25;q32) in multiple myeloma. MUM1 expression is seen in various B-cell lymphomas and predicts an unfavorable outcome in some lymphoma subtypes. To elucidate its role in B-cell ma...

journal_title：Leukemia

authors： Uranishi M,Iida S,Sanda T,Ishida T,Tajima E,Ito M,Komatsu H,Inagaki H,Ueda R

更新日期：2005-08-01 00:00:00

abstract：:Immunoglobulin (IG) gene repertoire restrictions strongly support antigen selection in the pathogenesis of chronic lymphocytic leukemia (CLL). Given the emerging multifarious interactions between CLL and bystander T cells, we sought to determine whether antigen(s) are also selecting T cells in CLL. We performed a larg...

journal_title：Leukemia

authors： Vardi A,Vlachonikola E,Karypidou M,Stalika E,Bikos V,Gemenetzi K,Maramis C,Siorenta A,Anagnostopoulos A,Pospisilova S,Maglaveras N,Chouvarda I,Stamatopoulos K,Hadzidimitriou A

更新日期：2017-07-01 00:00:00

abstract：:In order to further define the role of the MDR1 gene in acute myeloid leukemia (AML), we determined the association between the presence of P-glycoprotein on leukemic cells and the efficacy of therapy in patients with AML. Immunocytochemistry with monoclonal antibody C219 was performed to demonstrate the presence of P...

journal_title：Leukemia

authors： Zöchbauer S,Gsur A,Brunner R,Kyrle PA,Lechner K,Pirker R

更新日期：1994-06-01 00:00:00

abstract：:There is abundant evidence that leukemia arise through somatically acquired genetic changes. Familial or congenital predisposition is rarely involved. These genetic changes are often visible as chromosomal aberrations. Molecular analyses of the DNA sequences rearranged in leukemia has demonstrated the presence of cell...

journal_title：Leukemia

authors： Hagemeijer A

更新日期：1992-11-01 00:00:00

abstract：:A series of 60 acute nonlymphocytic leukemias (ANLL) was analyzed for the expression of terminal deoxynucleotidyl transferase (TdT). The detected TdT+ cells were studied in detail by use of double marker analyses for TdT and differentiation markers, such as myeloid markers (CD13 and CD33), B cell markers, T cell marke...

journal_title：Leukemia

authors： Adriaansen HJ,van Dongen JJ,Kappers-Klunne MC,Hählen K,van 't Veer MB,Wijdenes-de Bresser JH,Holdrinet AC,Harthoorn-Lasthuizen EJ,Abels J,Hooijkaas H

更新日期：1990-06-01 00:00:00

abstract：:Mucosa-associated lymphoid tissue (MALT) lymphoma is characterized by t(11;18)(q21;q21)/API2-MALT1, t(1;14)(p22;q32)/BCL10-IGH and t(14;18)(q32;q21)/IGH-MALT1, which commonly activate the nuclear factor (NF)-kappaB pathway. Gastric MALT lymphomas harboring such translocations usually do not respond to Helicobacter pyl...

journal_title：Leukemia

authors： Hamoudi RA,Appert A,Ye H,Ruskone-Fourmestraux A,Streubel B,Chott A,Raderer M,Gong L,Wlodarska I,De Wolf-Peeters C,MacLennan KA,de Leval L,Isaacson PG,Du MQ

更新日期：2010-08-01 00:00:00

abstract：:The t(15;17)(q22;q11-q21) translocation, a hallmark for acute promyelocytic leukemia (APL), has recently been shown to disrupt the retinoic acid-alpha receptor (RARA) gene localized on band 17q21. Leukemic cell DNAs from 16 Chinese patients with APL were analysed by Southern blot hybridization with probes covering the...

journal_title：Leukemia

authors： Chen Z,Chen SJ,Tong JH,Zhu YJ,Huang ME,Wang WC,Wu Y,Sun GL,Wang ZY,Larsen CJ

更新日期：1991-04-01 00:00:00

abstract：:Of 51 infants with acute leukemia, 13 (25%) had contradictory findings on 11q23/MLL rearrangements that were analyzed by cytogenetic and Southern blot methods: seven had rearranged MLL and normal karyotype, four had rearranged MLL and abnormal karyotype with no 11q23 translocation, and two had germline MLL and 11q23 t...

journal_title：Leukemia

authors： Watanabe N,Kobayashi H,Ichiji O,Yoshida MA,Kikuta A,Komada Y,Sekine I,Ishida Y,Horiukoshi Y,Tsunematsu Y,Yano M,Nakadate H,Kaneko Y

更新日期：2003-05-01 00:00:00

abstract：:The use of darbepoetin alfa to treat anemia in patients with lower-risk myelodysplastic syndromes (MDS) was evaluated in a phase 3 trial. Eligible patients had low/intermediate-1 risk MDS, hemoglobin ⩽10 g/dl, low transfusion burden and serum erythropoietin (EPO) ⩽500 mU/ml. Patients were randomized 2:1 to receive 24 ...

journal_title：Leukemia

authors： Platzbecker U,Symeonidis A,Oliva EN,Goede JS,Delforge M,Mayer J,Slama B,Badre S,Gasal E,Mehta B,Franklin J

更新日期：2017-09-01 00:00:00